Symptomatic finasteride users had “significantly lower International Index of Erectile Function composite score” and “significantly lower scores for each of its domains of erectile function, sexual desire, orgasmic function, intercourse satisfaction, and overall satisfaction”… There exists “a significant positive correlation between a subset of Beck Depression Inventory scores related to negative attitude and blood oxygen level dependent activity in the right nucleus accumbens, left pregenual anterior cingulate cortex, right insula, right lateral orbito-frontal cortex, and left posterior cingulate, as well as a negative correlation between BDI subscores and BOLD activity in the right parahippocampal/ fusiform gyrus. This neural circuitry overlaps with functional abnormalities that have been identified in major depression.”
Long-term adverse symptoms of men who used oral finasteride against androgenic alopecia have been recently described as post-finasteride syndrome (PFS). Aim: To determine whether (CAG)n-rs4045402 and (GGN)n-rs3138869 polymorphisms in the androgen receptor (AR) gene are implicated in PFS. Conclusion: This study showed that short and/or long (CAG)n and (GGN)n repeats had different frequencies according to symptoms reported by patients with PFS, likely reflecting the vast array of genes modulated by the AR. This study showed a U-curvilinear profile of (CAG)n repeats for skin dryness symptoms, where the two extremes exhibited a worse condition than medium repeats. Further studies are necessary to investigate the PFS pathophysiology using a precision medicine approach.
— Androgen Receptor (AR) Gene (CAG)n and (GGN)n Length Polymorphisms and Symptoms in Young Males With Long-Lasting Adverse Effects After Finasteride Use Against Androgenic Alopecia: Sabrina Cauci, The Journal of Sexual Medicine, November 2016.
In late 2015, the Canadian drug regulatory agency Health Canada announced that it had received 12 reports of suicidal thoughts or behaviour attributed to finasteride…Sexual dysfunction and suicidal ideation that appears to result from [finasteride] are important adverse effects. Patients should be informed of these risks, so that they can weigh the benefits of harms against treatment.
Recent evidence has shown that [finasteride], albeit generally well tolerated, can induce untoward psychological effects in a subset of patients; furthermore, this drug may have therapeutic efficacy for a number of different neuropsychiatric conditions, ranging from Tourette syndrome to schizophrenia. In rat models of these conditions, FIN has been shown to block the effects of dopamine receptors in the nucleusaccumbens (NAcc), a key terminal of the dopamine mesolimbic system. The biological underpinnings of these effects, however, remain mostly elusive… [O]ur results showed that FIN treatment affected the expression of a number of accumbal proteins involved in key functional processes, such as regulation of GABAergic neurotransmission, as well as steroid and pyrimidine metabolism. These findings may prove crucial to understanding the neurochemical mechanisms of FIN’s neuropsychiatric side effects, as well as its potential therapeutic properties for neurological and mental disorders.
Recent preclinical and clinical findings indicate that 5α-R inhibitors evoke not only beneficial, but also adverse effects. Future studies should investigate the biochemical and physiological mechanisms that underlie the persistence of the adverse sexual side effects to determine why a subset of patients is afflicted with such persistence or irreversible adverse effects. Also a better focus of clinical research is urgently needed to better define those subjects who are likely to be adversely affected by such agents.
— Adverse effects of 5α-reductase inhibitors: What do we know, don’t know, and need to know? Abdulmaged M. Traish, PhD, Prof. of Biochemistry and Urology, Boston University School of Medicine, Reviews in Endocrine and Metabolic Disorders, Sept. 16, 2015.
Users of finasteride…report serious physical and emotional adverse effects, collectively known as post-finasteride syndrome… Limited research exists exploring the psychological corollaries of post-finasteride syndrome and preexisting Axis I and Axis II mental health conditions… An important finding in this study was that almost 57% (n = 97) of men reported a psychiatric diagnosis and 28% (n = 27) had a first-degree relative with a mental health disorder, of this group 17 only had a family history. Nearly 50% of the men surveyed reported clinically significant depression as evidenced by Beck Depression Inventory score and 34% experienced anxiety on the Beck Anxiety Inventory.
[W]e have evaluated in male rats the effects of a subchronic treatment with low doses of finasteride…and the consequences of its withdrawal…on neuroactive steroid levels… [A]fter subchronic treatment…alteration in the levels of neuroactive steroids was observed. Moreover, increased expression of androgen receptor in the cerebral cortex and beta3 subunit of GABA-A receptor in the cerebellum was reported. Interestingly, at the withdrawal some of these effects persisted and different changes in neuroactive steroid levels, and in the expression of receptors were also detected. Altogether these findings suggest that the block of the enzyme 5alpha-reductase by finasteride treatment may have broad consequences for the nervous system.
Concern regarding adverse effects of finasteride is increasing. We aimed to determine the type and frequency of symptoms in men having long-term sexual and non-sexual side effects after finasteride treatment (a condition recently called post-finasteride syndrome, PFS)… Out of 79 participants… the most frequent sexual symptoms referred were loss of penis sensitivity (87.3%), decreased ejaculatory force (82.3%), and low penile temperature (78.5%). The most frequent non-sexual symptoms were reduced feeling of life pleasure or emotions (anhedonia) (75.9%); lack of mental concentration (72.2%), and loss of muscle tone/mass (51.9%)…Further studies are necessary to investigate the pathophysiological and biochemical pathways leading to the post-finasteride syndrome.
— An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia. Carlo Trombetta, MD, Urological Hospital, Departmentof Medical, Surgical and Health Sciences, University of Trieste, January 2016.
Conclusions: The data available in the contemporary literature on the adverse side effects of 5α-RIs do not conclusively suggest that these agents are safe to use in various subsets of patients. If the claimed safety profile indeed exists, then why there are so many patients treated with 5α-RIs seeking medical treatment for restoring their sexual function or recovery from their depression? Thus, the assertion that these drugs are well tolerated and safe is only in the eye of the beholder, and it is warranted to carefully reexamine the impact of the potential adverse effects of these agents not only on sexual function and psychological well-being, but also on other health concerns such as diabetes, bone metabolism, vascular disease, dementia, and cerebrovascular disease. Physicians bear the responsibility to give serious consideration to these adverse and sometimes debilitating and persistent side effects on patient health and discuss the potential adverse effects of these agents with their patients prior to commencing therapy.
— The Impact of the 5α-Reductase Inhibitors (5α-RIs) on Male
Sexual Function and Psychological Well-Being. Abdulmaged M. Traish, Department of Biochemistry, Boston University School of Medicine, August 2015.
Overview of Sexual Dysfunction (SD) and Suicidal Ideation (SI) Reports: A total of 15,518 adverse event reports were submitted [to the FDA] for low-dose finasteride between 1998 and 2013, corresponding to 4910 reports submitted for men aged 18–45 years. Persistent SD and SI adverse events accounted for 11.8% (577 reports) and 7.9% (39 reports), respectively, of the reports submitted for young men using low-dose finasteride. Approximately 87% (34/39 men) who had experienced SI had also reported SD. Conclusion: Our study suggests that young men receiving low-dose finasteride as treatment for androgenic alopecia are at risk of persistent SD, and this risk might contribute to SI.
— Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low-Dose Finasteride: A Pharmacovigilance Study. Ayad K. Ali, Global Patient Safety, Eli Lilly and Company. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, June 1, 2015.
Recent postmarketing reports and a US Food and Drug Administration analysis have documented uncommon persistent sexual and nonsexual side-effects in a subset of younger men who have taken finasteride 1 mg for androgenic alopecia. While the mechanisms of the sexual side-effects in humans is incompletely understood, one study found lower cerebrospinal fluid concentrations of dihydrotestosterone, progesterone, dihydroprogesterone and allopregnanolone, and higher levels of testosterone, 5α-androstane-3α,17β-diol and pregnenolone. Another study found up-regulation of the androgen receptor in the human foreskin with a mean of 5 years after finasteride discontinuation.
— Safety Concerns Regarding 5α Reductase Inhibitors for the Treatment of Androgenetic Alopecia. Michael S. Irwig, Center for Andrology and Division of Endocrinology, The George Washington University, Washington, D.C.
Conclusions: This study showed that long-term 5α-RIs therapy but not tamsulosin in men with BPH is associated with continued worsening of ED, which does not resolve with continue treatment, contrary to previous claims. Most importantly, it appears that 5α-RIs therapy but not tamsulosin results in reduction of T levels and increased AMS score as well as AST and ALT in liver. These findings raise a safety concern regarding 5α-RI therapy for the long-term. Clinicians are urged to discuss the impact of 5α-RIs therapy with their patients before commencing this therapy.
— Finasteride, Not Tamsulosin, Increases Severity of Erectile Dysfunction and Decreases Testosterone Levels in Men with Benign Prostatic Hyperplasia. Abdulmaged M. Traish, Boston University School of Medicine; Karim Sultan Haider, Private Urology Practice, Bremerhaven; Gheorghe Doros, Boston University School of Public Health; Ahmad Haider, Private Urology Practice, Bremerhaven. Hormone Molecular Biology and Clinical Investigation, June 6, 2015.
Conclusions: This report is the first to quantify the rate of persistent [sexual dysfunction] in healthy, young men exposed to finasteride ≤1.25 mg/day. Our findings indicate a need for increased awareness among patients and practitioners of the risk of persistent sexual dysfunction associated with use of finasteride for androgenic alopecia.
— Persistence of Sexual Dysfunction in Young Men Receiving Finasteride for Androgenic Alopecia: A Large Single Center Observational Cohort Study. Tina Kiguradze and Steven M. Belknap, Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
Results: Of 34 clinical trials, none had adequate safety reporting, 19 were partially adequate, 12 were inadequate, and 3 reported no adverse events. Funnel plots were asymmetric with a bias toward lower odds ratio for sexual adverse effects, suggesting systematic underdetection. No reports assessed adequacy of blinding, 18 (53%) disclosed conflicts of interest, and 19 (56%) received funding from the manufacturer. Duration of drug safety evaluation was 1 year or less for 26 of 34 trials (76%). Of 5704 men in the clinical data repository who were treated for AGA with finasteride, 1.25 mg/d or less, for [androgenetic alopecia], only 31% met inclusion criteria for the pivotal trials referenced in the manufacturer’s full prescribing information and 33% took finasteride for more than 1 year.
Conclusions and Relevance: Available toxicity information from clinical trials of finasteride in men with AGA is very limited, is of poor quality, and seems to be systematically biased. In a cohort of men prescribed finasteride for routine treatment of AGA, most would have been excluded from the pivotal studies that supported US Food and Drug Administration approval for AGA. Published reports of clinical trials provide insufficient information to establish the safety profile for finasteride in the treatment of AGA.
Post-finasteride syndrome is now a recognized condition, affecting as many as 20 per cent of those taking finasteride… The persistent sexual side-effects of finasteride may manifest after varying periods of taking the drug, or not until the drug is discontinued. It is not known why some men are susceptible to the potential adverse effects of finasteride, while others—the majority—are not affected… Further research is needed on who is susceptible to the persistent, adverse side-effects of finasteride and on the underlying mechanisms of the medication.
The effects in the brain of finasteride…have been poorly explored. Therefore, the effects of a subchronic treatment of finasteride…and the consequences of its withdrawal on neuroactive steroid levels in plasma, cerebrospinal fluid and some brain regions…have been evaluated in male rats. After subchronic treatment…the following effects were detected: (i) depending on the compartment considered, alteration in the levels of neuroactive steroids, not only in 5alpha-reduced metabolites but also in its precursors and in neuroactive steroids from other steroidogenic pathways and (ii) upregulation of androgen receptor in the cerebral cortex and beta3 subunit of GABA-A receptor in the cerebellum. One month after the last treatment (i.e., withdrawal period), some of these effects persisted…Moreover, other changes in neuroactive steroid levels, steroid receptors…and GABA-A receptor subunits…were detected. These findings suggest that finasteride treatment may have broad consequences for brain function.
— Effects of Subchronic Finasteride Treatment and Withdrawal on Neuroactive Steroid Levels and their Receptors in the Male Rat Brain: Silvia Giatti, PhD. Neuroendocrinology: International Journal for Basic and Clinical Studies on Neuroendocrine Relationships, Dec. 9, 2015
Recent postmarketing studies and the [FDA] have found that finasteride, 1 mg, for androgenic alopecia has been associated with persistent sexual and nonsexual adverse effects… The present study was designed to assess whether otherwise healthy former users of finasteride with persistent sexual adverse effects have a higher prevalence of low serum androgens and spermatogenic deficits… 3 of 19 participants (16%) [had] severe oligospermia (<5 million/mL). The mean and median motilities were 50% (23%) and 50%, respectively, with 4 of 9 participants (44%) having 2 confirmed low motility.
Finasteride is a synthetic 5-α reductase inhibitor, which prevents the conversion of testosterone to dihydrotestosterone and has been used for more than 20 years in the treatment of male pattern hair loss. Randomized, controlled trials have associated finasteride with both reversible and persistent adverse effects. In this pilot study, we sought to characterize sexual and nonsexual adverse effects that men reported experiencing at least 3 months after stopping the medication. Based on previous research on persistent side effects of finasteride, we constructed an Internet survey targeting six domains: physical symptoms, sexual libido, ejaculatory disorders, disorders of the penis and testes, cognitive symptoms, and psychological symptoms and was e-mailed to patients who reported experiencing symptoms of side effects of finasteride. Responses from 131 generally healthy men (mean age, 24 years) who had taken finasteride for male pattern hair loss was included in the analysis. The most notable finding was that adverse effects persisted in each of the domains, indicating the possible presence of a “post-finasteride syndrome.”
Conclusions: This study significantly extends understanding of the effects of long-term treatment with these drugs on sexual function in men with lower urinary tract symptoms associated with benign prostatic hyperplasia. Treatment with finasteride or combined therapy was associated with worsening sexual function while treatment with doxazosin alone was associated with minimal negative impact, if any. Physicians should discuss with their patients the possible long-term effects of these drugs for lower urinary tract symptoms associated with benign prostatic hyperplasia on sexual function.
— Change in Sexual Function in Men with Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Associated with Long-Term Treatment with Doxazosin, Finasteride and Combined therapy. CW Fwu, Journal of Urology, June 2014.
Summary: “A substantial body of evidence exists which points to serious and potentially ill-health effects of [finasteride and dutasteride] therapy. These include loss or reduced libido, erectile dysfunction, orgasmic and ejaculatory dysfunction, development of high grade PCa tumors, potential negative cardiovascular events, and depression. The side effects are potentially harmful in some individuals and in young men may be persistent or irreversible. The argument that the benefits of these drugs outweighs the risks is slowly eroding in the face of new emerging scientific evidence from preclinical and clinical studies. The available data demonstrate that such drugs do pose serious adverse effects, especially in a subset of men who may have the predisposition to be affected severely. This is also corroborated by the overwhelming FDA disapproval of these drugs for the chemoprevention of PCa. The FDA mandated relabeling issued in 2011 equally points to the dark side of these drugs on human health. Physicians need to be aware of the adverse side effects of these drugs and are encouraged to share this information with their patients prior to commencing therapy with finasteride or dutasteride.
— The Dark Side of 5α-Reductase Inhibitors’ Therapy: Sexual Dysfunction, High Gleason Grade Prostate Cancer and Depression. Traish, A.M. Korean J Urol. 2014 Jun;55(6):367-79. doi: 10.4111/kju.2014.55.6.367. Epub 2014 Jun 16.
Observations performed in a subset of patients treated for male pattern hair loss indicate that persistent sexual side effects as well as anxious/depressive symptomatology have been reported even after discontinuation of finasteride treatment. Due to the capability of finasteride to block the metabolismof progesterone (PROG) and/or testosterone (T) we have evaluated, by liquid chromatography–tandemmass spectrometry, the levels of several neuroactive steroids in paired plasma and cerebrospinal fluid (CSF) samples obtained from post-finasteride patients and in healthy controls. At the examination, post-finasteride patients reported muscular stiffness, cramps, tremors and chronic fatigue in the absence of clinical evidence of any muscular disorder or strength reduction. Although severity of the anxious/depressive symptoms was quite variable in their frequency, overall all the subjects had a fairly complex and constant neuropsychiatric pattern…The present observations show that altered levels of neuroactive steroids, associated with depression symptoms, are present in androgenic alopecia patients even after discontinuation of the finasteride treatment.
— Patients Treated for Male Pattern Hair with Finasteride Show, After Discontinuation of the Drug, Altered Levels of Neuroactive Steroids in Cerebrospinal Fluid and Plasma. Caruso, D., Melcangi R.C. J. Steroid Biochem. Mol. Biol. (2014)
Background: There have been reports for over a decade linking serotonin reuptake inhibitors, finasteride and isotretinoin with enduring sexual dysfunction after treatment stops.
Methods: We have selected 120 reports to RxISK.org reporting the problem and mined these for data on age, gender, drug of use, and impact of the problem.
Results: The data make it clear that the three drugs show extensive overlap in symptom profile, regardless of sex or country of origin.
Conclusions: The availability of 120 reports from over 20 countries add to the case for the validity of the syndrome. This is severe and enduring condition can result in death. An understanding of its physiology and an approach to treatment are needed.
Finasteride is a steroid 5-alpha-reductase inhibitor, approved for the treatment of androgenetic alopecia (AGA) and benign prostate hyperplasia. In some patients the treatment is associated with adverse side effects that could become persistent after therapy discontinuation, resulting in the so-called post-finasteride syndrome (PFS). A pharmacogenetic component in the response to finasteride treatment was previously demonstrated. Two polymorphisms (CAG) rs4045402 and (GGN) rs3138869 in the gene encoding for the androgen receptor (AR) have been hypothesized to play a role in finasteride sensitivity. We aimed to compare the rs4045402 and rs3138869 polymorphisms prevalence in a group of 69 selected subjects (AGA+PFS) that used finasteride to treat alopecia and developed persistent side effects, with that in a group of 91 untreated subjects with AGA (AGA), and a group of 76 untreated subjects without AGA (NO-AGA). The rs4045402 and rs3138869 polymorphisms extreme-lengths alleles were more frequent among AGA+PFS (odds ratio, 5.88; 95% CI, 1.87-18.52) and AGA subjects (odds ratio, 3.55; 95% CI, 1.13-11.21) than among NO-AGA subjects, probably reflecting the genetic predisposing factors for AGA development. In conclusion, we described a predictive effect of the less common repeats’ length CAG-rs4045402 and GGN-rs3138869 on AGA development.
— A Pharmacogenetic Survey of Androgen Receptor (CAG)n and (GGN)n Polymorphisms in Patients Experiencing Long-term Side Effects After Finasteride Discontinuation. Cecchin, E., De Mattia, E., Mazzon, G., Cauci, S., Trombetta, C., Toffoli, G. Int J Biol Markers. 2014 May 17:0. doi: 10.5301/jbm.5000095.
Finasteride is still one of the most common therapeutic drugs prescribed for AGA, a distinctive alopecia pattern involving hairline recession and vertex balding, a condition more frequent with increasing age… However, treatment of young subjects is of increasing concern due to accumulating evidence that daily use of oral finasteride has several severe adverse effects. Our main finding was the assessment of a significant increase of AR nuclear levels in some types of cells, specifically, stromal and epithelial cells, in dermis samples of foreskin from patients with major sexual adverse side-effects long after use of finasteride (on average almost 5 years later). As our patients are suffering from symptoms suggestive of local androgens deficiency, it was important to assess if this phenomenon was due to intrinsic inability to express and/or translocate the AR into the cell nuclei, specifically in the genital tissues… Since finasteride inhibits T conversion into DHT, which is responsible for most androgen activity, it is plausible that prolonged finasteride use in predisposed individuals could simulate the effects of aging in young men. Since some of the effects of androgen inhibition cannot be reversed once local androgen levels are re-established, it is temping to speculate that patients could still suffer from adverse sexual effects several months or even permanently after finasteride discontinuation because of aging effects caused prematurely by androgens deprivation, namely by artificially reduced DHT concentrations.
— Immunohistochemical Evaluation of Androgen Receptor and Nerve Structure Density in Human Prepuce from Patients with Persistent Sexual Side Effects after Finasteride Use for Androgenetic Alopecia. Di Loreto, C., La Marra, F., Mazzon, G., Belgrano, E., Trombetta, C., Cauci, S. PLoS One. 2014 Jun 24;9(6):e100237. doi: 10.1371/journal.pone.0100237
Two studies evaluating the sexual function in men with Lower Urinary Tract Symptoms (LUTS) as well as post bilateral nerve-sparing radical prostatectomy were presented to the media at a special press conference during the 2014 Annual Scientific Meeting of the American Urological Association (AUA):
Erectile dysfunction following radical prostatectomy for clinically localized prostate cancer is a known side effect to the surgery; however with the introduction of the nerve-sparing radical prostatectomy technique, many men can expect to recover erectile function, but early recovery of natural erectile function is not common. Increasing attention has been given to this concern in recent years and is why researchers from Canada, the United States and five European countries compared the efficacy and protective effect of Tadalafil (a phosphodiesterase type 5 inhibitor approved to treat erectile dysfunction), on penile function after nerve-sparing radical prostatectomy. Results showed:
—Men taking Finasteride experienced significant worsening of ejaculatory function than those not.
—Men prescribed both Doxazosin and Finasteride also experienced significant worsening in erectile function and sexual problem assessment.
Overview. Melasma is an acquired hypermelanosis that typically affects sun-exposed areas on the face and presents as symmetric brownish macules and patches coalescing in a reticular pattern. An estimated 6 million women in the US and 45-50 million women worldwide are affected by melasma. Men comprise 10% of the affected population… Finasteride is currently approved for the treatment of benign prostatic hyperplasia (BPH) and androgenetic alopecia. It exerts its effects via inhibition of 5α-reductase, the enzyme, which converts testosterone to dihydrotestosterone. Decreased libido, sexual dysfunction, depression, and gyencomastia have been reported as side effects of finasteride use for BPH.5-10 These side effects are thought to be subsequent to the hormonal changes induced by finasteride. We report here the case of one patient who developed melasma post treatment with low-dose finasteride (trade name Propecia) for androgenetic alopecia. We hypothesize that hormonal changes elicited by finasteride use for androgenetic alopecia are responsible for the development of melasma in select patients.
Conclusions. Persistent adverse effects of finasteride in younger men include erectile dysfunction, low libido, lack of
orgasms, depression, and decreased alcohol consumption. One study has found lower levels of several neurosteroids
in this population. Out of the various persistent side effects, erectile dysfunction and decreased alcohol consumption
have been the most studied in animal models. Further research is needed on who is susceptible to the persistent
adverse side effects of finasteride and on the underlying mechanisms of the medication.
Background: There is a robust literature in rodents, but not in humans, on the interaction between finasteride and alcohol, particularly as it relates to neurosteroids. Finasteride has been shown to reduce alcohol intake and suppress alcohol preference in male mice. This study examines the role of finasteride in alcohol consumption in humans with male pattern hair loss.
Results: Of the 63 men who consumed at least 1 alcoholic beverage/wk prior to starting finasteride, 41 (65%) noted a decrease in their alcohol consumption after stopping finasteride. This reduction typically began before discontinuing finasteride. Twenty men (32%) reported no change in their alcohol consumption, and 2 men (3%) reported an increase in their alcohol consumption. For the 63 consumers of alcohol, the mean number (±SE) of alcoholic beverages/wk declined from 5.2 ± 0.7 before finasteride to 2.0 ± 0.3 after finasteride (p < 0.0001). A major study limitation is the lack of a comparison group.
Conclusions: In former male users of finasteride who developed persistent sexual side effects, 65% noticed a decline in their alcohol consumption as compared to baseline. This finding is consistent with finasteride’s ability to modulate alcohol intake in rodents. Further research is needed on the central nervous system effects of finasteride in humans.
— Decreased Alcohol Consumption Among Former Male Users of Finasteride with Persistent Sexual Side Effects: A Preliminary Report. Michael S. Irwig, M.D., F.A.C.E., assistant professor of medicine at the George Washington University School of Medicine and Health Sciences, and director of the Center for Andrology at The GW Medical Faculty Associates. Alcoholism: Clinical and Experimental Research. June 13, 2013. DOI: 10.1111/acer.12177.
Introduction: Observations performed in a subset of subjects treated with finasteride (an inhibitor of the enzyme 5α-reductase) for male pattern hair loss seem to indicate that sexual dysfunction as well as anxious/depressive symptomatology may occur at the end of the treatment and continue after discontinuation.
Aim: A possible hypothesis to explain depression symptoms after finasteride treatment might be impairment in the levels of neuroactive steroids. Therefore, neuroactive steroid levels were evaluated in paired plasma and cerebrospinal fluid samples obtained from male patients who received finasteride for the treatment of androgenic alopecia and who, after drug discontinuation, still show long-term sexual side effects as well as anxious/depressive symptomatology.
Conclusion: The present observations confirm that an impairment of neuroactive steroid levels, associated with depression symptoms, is still present in androgenic alopecia patients treated with finasteride despite the discontinuation of the treatment.
— Neuroactive Steroid Levels are Modified in Cerebrospinal Fluid and Plasma of Post-Finasteride Patients Showing Persistent Sexual Side Effects and Anxious/Depressive Symptomatology. Roberto Cosimo Melcangi PhD. The Journal of Sexual Medicine. Volume 10, Issue 10, pages 2598–2603, October 2013.
Expert opinion: Clinical trials with 5ARI report prevalence rates of de novo erectile dysfunction of 5 – 9%. Decreased circulating dihydrotestosterone (DHT) resulting from 5ARI use is associated with diminished sexual desire and/or orgasm. The presence of adverse sexual effects is associated with decreased self-esteem, quality of life and ability to maintain an intimate relationship. Inhibition of 5ARI additionally influences progesterone and deoxycorticosterone levels and may alter psychological functions, including increased depression, melancholy and loss of general well being. Ejaculatory dysfunction has not been well studied in patients using 5ARI. Patients receiving therapy with 5ARI should be counseled as to potential sexual and psychological adverse effects. Future clinical studies are needed to further investigate the sexual side effects associated with this class of drugs.
— Effects of 5-alpha Reductase inhibitors on erectile function, sexual desire and ejaculation. Serap Gur, Tulane University Health Sciences Center, January 2013, Vol. 12, No. 1 , Pages 81-90 (doi:10.1517/14740338.2013.742885)
- 5α-reductases are a family of isozymes that play a critical role in transformation not only of testosterone but also of progesterone, DOC, aldosterone and cortisol into a host of neuro-active steroids that regulate multitude of functions in human physiology…. the neuro-active steroid hormones modulate multitude of functions in human physiology encompassing regulation of sexual differentiation, neuro-protection, memory enhancement, anxiety, sleep and stress, among others.
- Until recently, the adverse effects of 5α -reductase inhibitor therapy were thought to be very minor and well tolerated (80, 81, 82). However, new information suggests that these drugs may impair sexual function including sexual desire, erectile and orgasmic function [Table 3](for review cf. 83, 84). Recent studies in animal models suggested that these agents alter penile tissue histo-architecture and nitric oxide synthase function in penile tissue and thus can contribute to erectile dysfunction (85, 86, 87).
- It is particularly important to note that in a subset of patients, the effects of these drugs are long lasting and may be irreversible (84). An association between use of these inhibitors and depression is also noted (88), suggesting potential adverse effect on the brain.
- A number of case reports have suggested that 5α-reductase inhibitors therapy is associated with angioedema ( 91); cataract and intraoperative floppy-iris syndrome (92), pseudoporphyria, (93),T cell–mediated acute localized exanthematous pustulosis (94) and gyncomastia and male breast cancer (28, 95).
- The recent introduced warnings on the drug labeling also suggests that increased awareness of the potential irreversible side effects of these agents [FDA].”
— 5α-Reductases in Human Physiology: An Unfolding Story. Abdulmaged M. Traish, PhD, MBA. Department of Urology, Boston University School of Medicine, Boston, Massachusetts, USA. Endocrine Practice (July 2012), 1530-891X (Print), 10.4158/EP12108.RA
- In a group of 54 otherwise healthy former users of finasteride who developed persistent sexual side effects that lasted for at least 3 months, 96% continued to experience these effects when reassessed 9–16 months (mean 14 months) later, raising the possibility of permanent effects.
- To explain the long-term neurological effects of finasteride, it is possible that reduced concentrations of neuroactive steroids are affecting the plasticity of neuronal architecture in regions of the brain responsible for sexual function.
- The most volunteered changes related to the urogenital system in terms of semen quality and decreased ejaculate volume, reduction in penis size, penile curvature or reduced sensation, fewer spontaneous erections, decreased testicular size, testicular pain, and prostatitis. Many subjects also noted changes to their mental abilities, sleeping patterns, and/or depressive symptoms. Many subjects reported a “disconnection” between the mental and physical aspects of sexual function.
- Further valuable research could determine who would be susceptible to finasteride through genetic studies of polymorphisms of 5a reductase and the androgen receptor. Further research with validated instruments is needed to study the nonsexual persistent side effects associated with finasteride.”
- In a group of 61 otherwise healthy former users of finasteride who developed persistent sexual side effects, depressive symptoms were present and categorized as mild in 11% of users, moderate in 28% of users, and severe in 36% of users. Suicidal thoughts were present in 39% of former finasteride users, and an additional 5% chose the statement “I would like to kill myself.”
- The corresponding rates of depressive symptoms and suicidal thoughts were significantly lower in a control group of young men with male pattern hair loss who had not used finasteride and who did not have any current or past psychiatric conditions or use of psychiatric medications.
- It turns out that finasteride crosses the blood-brain barrier and blocks the enzyme 5α-reductase, which reduces the concentrations of multiple neuroactive steroids derived not only from testosterone, but also from progesterone and deoxycorticosterone…. reduced concentrations of neuroactive steroids are associated with depression in several human studies.
- Although the effects of finasteride in the human brain are poorly understood, clinicians, as well as potential finasteride users, should be aware of the serious potential risks of this medication, especially as it is being used cosmetically to alter a normal age-related process. This is the first study to document suicidal thoughts in (former) users of finasteride.”
— Depressive Symptoms and Suicidal Thoughts Among Former Users of Finasteride With Persistent Sexual Side Effects. Michael S. Irwig, MD, Division of Endocrinology, Medical Faculty Associates and George Washington University. J Clin Psychiatry (August 2012), 10.4088/JCP.12m07887
- 5a-RIs therapy, while improving urinary symptoms in patients with BPH and may prevent hair loss, produce significant adverse effects in some individuals including loss of libido, ED, ejaculatory dysfunction, and potential depression. They are serious enough to preclude them from pursuing such therapy.
- The effects of these agents on vascular health should also be noted in light of recent findings that patients treated with 5a-RIs therapy had significant adverse cardiovascular events.
- These observations suggest that extreme caution should be exercised prior to prescribing 5a-RIs therapy to patients for hair growth or for BPH symptoms.”
— Adverse Side Effects of 5α-Reductase Inhibitors Therapy: Persistent Diminished Libido and Erectile Dysfunction and Depression in a Subset of Patients. Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML. J Sex Med. 2011 Mar;8(3):872-84.
We report a case of unintended use of finasteride during early pregnancy. The pregnancy ended with the normal delivery of a baby girl with unilateral hand and toe deformities. A 41-year-old woman…was urgently referred to the Maternal-Fetal Medicine clinic at King Fahad Medical City. She was seeing a dermatologist due to male pattern alopecia after her last delivery. Finasteride 1 mg was prescribed, and she was warned against pregnancy. However, she did not use contraception because she was breastfeeding and thought she would not become pregnant. Unfortunately, pregnancy was confirmed after a history of 6 weeks of amenorrhea. Finasteride was stopped immediately. She had six previous healthy children and was not known to have any chronic medical illnesses. The family history was unremarkable for congenital anomalies or genetic diseases. She used no medication other than finasteride and there was no history of radiation exposure…A detailed anatomy ultrasound scan at 18 and 26 weeks of gestation found no anomalies. Because the fetus was a female, the mother was reassured. For the rest of her antenatal care, the pregnancy was uneventful… [Her] baby was found to have deformities in the right hand in the form of a small hand with short fingers and absent phalangial bones in all five fingers (aphalangia), and in the left foot in the form of short second and third toes with absent distal phalanges. Two cafe au lait spots were seen also on the back…To our knowledge, this is the first case report of finasteride use during pregnancy in a human. It is not clear if these deformities are related to finasteride use in pregnancy, but it is worthwhile to document a possible association and focus attention on the possibility of limb deformities in such cases.
- A subset of otherwise healthy men taking finasteride for MPHL developed persistent sexual side effects in temporal association with the medication. Most men developed sexual dysfunction in multiple domains with 94% experiencing low libido, 92% experiencing erectile dysfunction, 92% experiencing decreased arousal, and 69% experiencing problems with orgasm.
- The mean duration of the persistent sexual side effects was at least 40 months, with 20% of subjects reporting durations of over 6 years. The mean number of sexual episodes per month dropped from 25.8 before finasteride to 8.8 after finasteride (P < 0.0001). The total sexual dysfunction score increased from 7.4 to 21.6 for before and after finasteride use (P < 0.0001).
- Physicians treating MPHL should discuss the potential risk of persistent sexual side effects associated with finasteride.”
- Finasteride has been associated with reversible adverse sexual side effects in multiple randomized, controlled trials. The mentioned side effects are described as reversible. However in literature a lot of case of persistent sexual adverse symptoms are signaled. The persistence of symptoms after discontinuation is named Post-Finasteride Syndrome (PFS).
- Patients were aged 24-56. ASEX evaluated before and after finasteride assumption had a mean decreasing of 13,84 (P<0.05). No statistically significant differences were observed in relation to the duration of therapy or to the age of assumption. 60% of patients reported that their symptoms worsened after discontinuation of the drug.
- The finasteride used in young males should determine a potential risk for sexual health, physicians treating MPHL should evaluate the potential risk of persistent sexual side effects associated with finasteride.”
— Clinical analysis in young patient with persistent sexual dysfunctions after finasteride assumption to prevent male pattern hair loss.Trombetta, C.; Mazzon, G.; Liguori, G.; Ollandini, G.; Cauci, S.; Toffoli, G.; Erika, E.. European Urology – Supplements. 2012 Feb 2; e698,e6-NaN.